Alzheimer’s and Alzheimer-related dementia represent a group of heterogeneous and multifactorial diseases with several molecular subtypes. Therefore, there is no single silver bullet to fight this group of diseases. For the next generation of Alzheimer-related dementia drug development pipeline, we need to shift the paradigm. Advances in molecular profiling and multi-omic approaches could accelerate the next generation of AD and related dementia drug discovery...
Alzheimer’s and Alzheimer-related dementia represent a group of heterogeneous and multifactorial diseases with several molecular subtypes. Therefore, there is no single silver bullet to fight this group of diseases. For the next generation of Alzheimer-related dementia drug development pipeline, we need to shift the paradigm. Advances in molecular profiling and multi-omic approaches could accelerate the next generation of AD and related dementia drug discovery. And this is going to be where biology meets precision medicine. We can leverage omics discovery to amplify the next generation of drug discovery. And this will come from gene-targeted therapy and accurate molecular biomarkers that will enable precision medicine approaches. I invite the audience of this video interview to watch our podcast series, Empowering Proteomics and Transcriptomics in Alzheimer’s Drug Discovery, where we have in-depth conversations about various aspects on these topics, including promises and challenges along the road.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
